Core Attributes
|
Attribute |
Value |
Source |
|
Chemical Structure |
Palmitoyl tripeptide-1 (Pal-GHK) + Palmitoyl tetrapeptide-7 (Pal-GQPR) |
|
|
Amino Acid Sequence |
Gly-His-Lys + Gly-Gln-Pro-Arg with palmitoyl fatty acid chains |
|
|
Molecular Weight |
Low molecular weight (penetration-optimized) |
|
|
Mechanism Class |
Matrikine messenger peptides (signal molecules) |
|
|
Primary Function |
Extracellular matrix regulation and cell proliferation activation |
|
|
Clinical Efficacy |
45% reduction in deep wrinkles after 2 months |
|
|
Collagen Stimulation |
Increases type I collagen synthesis in fibroblasts |
|
|
Elastin Stimulation |
Promotes elastin production |
|
|
Gene Expression |
Upregulates dermal and epidermal matrix genes |
|
Application Attributes
|
Application Type |
Condition Treated |
Formulation |
|
Anti-aging serums |
Fine lines, wrinkles, loss of firmness |
3-8% concentration |
|
Eye creams |
Crow's feet, periorbital wrinkles |
3-5% concentration |
|
Firming treatments |
Loss of elasticity, sagging |
5-8% concentration |
|
Post-procedure care |
Collagen restoration after treatments |
3-5% concentration |
|
Wound healing |
Accelerated tissue repair |
0.1-1% concentration |
Mechanism Attributes
Palmitoyl Tripeptide-1
|
Mechanism |
Effect |
Evidence |
|
Fibroblast receptor binding |
Activates TGF-β-like signaling pathway |
|
|
Collagen gene transcription |
Increases type I and type III collagen mRNA |
|
|
Collagenase inhibition |
Prevents collagen degradation |
|
|
Extracellular matrix protein synthesis |
Increases fibronectin, glycosaminoglycans |
|
Palmitoyl Tetrapeptide-7
|
Mechanism |
Effect |
Evidence |
|
Anti-inflammatory action |
Reduces IL-6 cytokine production |
|
|
Tissue repair promotion |
Accelerates wound healing process |
|
|
Matrix remodeling support |
Reduces inflammation-induced collagen breakdown |
|
Clinical Data Attributes
|
Study Parameter |
Baseline |
2 Months |
Percentage Change |
Source |
|
Deep wrinkle depth |
Baseline measurement |
45% reduction |
-45% |
|
|
Wrinkle volume |
Baseline measurement |
Significant reduction |
Not specified |
|
|
Wrinkle density |
Baseline measurement |
Significant reduction |
Not specified |
|
|
Skin elasticity |
Baseline measurement |
Increased |
Not quantified |
|
|
Skin smoothness |
Baseline measurement |
Improved |
Not quantified |
|
|
Collagen synthesis (in vitro) |
Control (100%) |
Increased at 1%, 3%, 5% |
Dose-dependent |
|
Sourcing Attributes
|
Attribute |
Value |
|
Synthesis Method |
Solid-phase peptide synthesis (Fmoc strategy) |
|
Starting Material |
Amino acids (glycine, histidine, lysine, glutamine, proline, arginine) |
|
Lipophilic Modification |
Palmitoyl (16-carbon fatty acid chain) attachment to N-terminus |
|
Purity Standard |
≥97% (HPLC-verified) |
|
CAS Number |
214047-00-4 (Palmitoyl pentapeptide-4 related) |
|
Formulation Variants |
MATRIXYL-3000 OS (oil-soluble), MATRIXYL-3000 Glyx (water-soluble) |
|
Quality Control |
Mass spectrometry, HPLC assay, Karl Fischer moisture, pH testing |
Dosage Attributes
|
Parameter |
Value |
Source |
|
Topical Concentration |
3-8% in finished products |
|
|
Standard Concentration |
5% (typical anti-aging formulation) |
|
|
Wound Healing Concentration |
0.1-1 mg/mL |
|
|
Application Frequency |
Twice daily (morning and evening) |
|
|
Minimum Treatment Duration |
2 months for measurable wrinkle reduction |
|
|
Optimal Treatment Duration |
3-6 months for maximum collagen accumulation |
|
|
Results Timeline |
Week 2-4: Initial firmness improvement |
|
|
Results Timeline |
Week 8: 45% deep wrinkle reduction |
|
|
Results Timeline |
Week 12+: Continued elasticity enhancement |
|
How Matrixyl 3000® Works in YourHappyLife Formulations
Integration: YourHappyLife incorporates Matrixyl 3000® as clinically proven peptide blend that stimulates collagen and elastin, reducing wrinkles and improving firmness, smoothness, and visible skin bounce naturally.
Synergistic Mechanism:
-
Palmitoyl tripeptide-1 → Binds fibroblast receptors → Activates TGF-β signaling → Increases collagen I/III transcription → Net collagen accumulation
-
Palmitoyl tetrapeptide-7 → Reduces IL-6 inflammation → Protects collagen from inflammatory degradation → Supports tissue repair
-
Combined effect → 45% wrinkle depth reduction in 8 weeks
Safety Attributes
|
Safety Parameter |
Status |
Source |
|
Regulatory Status |
Approved cosmetic ingredient |
|
|
Cytotoxicity |
Non-cytotoxic at therapeutic concentrations |
|
|
Skin Irritation |
Non-irritating (clinical patch testing) |
|
|
Sensitization |
No sensitization observed |
|
|
All Skin Types |
Suitable including sensitive skin |
|
|
Pregnancy Safety |
Generally recognized as safe (topical) |
|
|
Periorbital Use |
Safe for eye area application |
|
|
Comedogenicity |
Non-comedogenic |
|
|
Photosensitivity |
None |
|
|
Long-term Use |
Suitable for continuous daily application |
|
Product Compatibility Attributes
|
Compatible Ingredient |
Synergy Effect |
|
Hyaluronic acid |
Enhanced hydration + collagen support |
|
Vitamin C |
Collagen cofactor + antioxidant protection |
|
Niacinamide |
Barrier support + anti-inflammatory |
|
Retinoids |
Complementary collagen pathways (apply separately) |
|
Peptides (other) |
Multi-pathway collagen stimulation |
|
Ceramides |
Barrier integrity during collagen remodeling |
|
Antioxidants |
Protection of newly synthesized collagen |
No Negative Interactions: Compatible with standard skincare actives
